Recent News

• 02.12.2026 - Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update
• 11.17.2025 - Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference
• 11.13.2025 - Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update
• 11.11.2025 - Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting
• 10.23.2025 - Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review

Recent Filings

• 02.12.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 02.12.2026 - EX-99.1 EX-99.1
• 02.12.2026 - 8-K Current report
• 01.28.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.12.2026 - 8-K Current report
• 01.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 11.17.2025 - 10-Q/A Quarterly report [Sections 13 or 15(d)]